In­tel­lia, Verve run clin­i­cal tri­als abroad amid FDA’s ‘cau­tious’ ap­proach to gene edit­ing

In­tel­lia Ther­a­peu­tics an­nounced ear­li­er this month that it would run a mid-stage tri­al of a CRISPR-based treat­ment for a rare ge­net­ic dis­ease called hered­i­tary an­gioede­ma (HAE) en­tire­ly out­side of the US. The de­ci­sion came af­ter the FDA asked for more re­search on re­pro­duc­tive ef­fects if the tri­al was to in­clude women of child-bear­ing age.

So far, at least two gene edit­ing com­pa­nies — In­tel­lia and Verve Ther­a­peu­tics — have de­cid­ed to run ear­ly- or mid-stage clin­i­cal tri­als out­side the US, as FDA takes a more cau­tious ap­proach than for­eign reg­u­la­tors to the nascent field of gene edit­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER